IMPACT Medicom
We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic areas. If you like our podcast, please take the time to rate it and subscribe. See our website for more information, video capsules, and podcasts at: https://www.impactmedicom.com.
Podcasting since 2020 • 70 episodes
IMPACT Medicom
Latest Episodes
Prise en charge de la PN associée au BV utilisé pour le traitement de première intention du cH
(FRENCH) In this podcast episode, which follows this introduction in French, Dr Christopher Lemieux summarizes a paper by Dr Abramson, et al. on the management of Peripheral Neuropathy Associated with Brentuximab Vedotin in the Frontline Treatm...
•
14:53
Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in cHL
In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma. Our GuestDr. Michael Chu is...
•
19:42
ASH 2024: Updates on CLL
In this podcast episode, Dr. Versha Banerji, a Canadian hematologist from Manitoba and Dr. Jennifer Brown, an internationally renowned hematologist from the United States, discuss data on the treatment of CLL presented at the American Society o...
•
26:34
Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape
In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest:Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Re...
•
17:37
Highlights from EHA 2024 - Updates on the Treatment of CLL
In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of the data from 6 oral pr...
•
42:13